Moonlight Bio
Thomas Galbo is a seasoned biomedical professional with extensive experience in advisory and leadership roles across various companies. Currently serving as an Advisor at both Moonlight Bio and Leveragen while also advising Kelonia Therapeutics, Galbo previously held positions such as Chief Business and Operating Officer at Hillstar Bio and Chief Business Officer at Kelonia Therapeutics. Notably, experience includes a significant tenure at bluebird bio, where roles included Vice President of Oncology Corporate Development and Program Leader for the ABECMA CAR T Program. Additional experience encompasses consulting at The Boston Consulting Group and research at Yale University School of Medicine. Galbo holds a PhD in endocrinology from the University of Copenhagen, where previous studies also culminated in MSc and BSc degrees in Molecular Biomedicine.
Moonlight Bio
Moonlight Bio is a Seattle-based, preclinical stage biotech company pioneering the development of cutting-edge cell therapies for the treatment of cancer. Our team is comprised of highly collaborative individuals who are passionate about designing highly innovative technologies and candidates with the potential to transform the lives of cancer patients. Engaging across the full landscape of drug development, Moonlight’s team members are pursuing opportunities in discovery research, component design and screening, preclinical modeling, process and analytical development, translational and clinical studies, and partnerships necessary to enable and advance our core technologies. We believe in fostering a healthy work-life balance, and when we’re not busy in the lab, we enjoy the natural beauty and recreational activities that the Pacific Northwest has to offer. We love to collaborate! Reach out to us: info@moonlightbio.us